Researchers at North Carolina State University achieved dramatic pDNA yield enhancements by controlling E. coli evolution, a step that promises to lower gene therapy manufacturing costs. Meanwhile, Absci and Almirall expanded an AI-driven antibody discovery collaboration aiming for dermatology treatments, leveraging generative AI with synthetic biology. Empatica launched a compact AI-powered wearable, EmbraceMini, cleared by the FDA, designed for real-time clinical trial monitoring with high data quality. These advances reflect combined innovations in biomanufacturing, AI drug design, and digital health monitoring shaping next-generation biopharma capabilities.